XTalks

MARCH 7, 2024

Breast Cancer Multiomics: Unified Insights in Tumor Heterogeneity This on-demand webinar introduces a cutting-edge single-cell multiomics method designed for garnering detailed genetic insights into breast cancer. The test accurately identified a range of genetic abnormalities, including trisomies and microdeletions.

Genetics 115

Genetics Hormones Genome Genomics 115

XTalks

JANUARY 26, 2023

Diagnosis is confirmed by a differential complete blood count and genetic testing. Treatment selection is determined by age, disease severity, comorbidities and the presence or absence of certain genetic mutations. As with many cancers, CLL and SLL are more difficult to treat in the relapse/refractory setting.

FDA Approval 97

FDA Approval Life Science Clinical Trials Clinical Trials 97

XTalks

JANUARY 6, 2021

One nanobody in particular, called NIH-CoVnb-112, was shown to be able to prevent COVID-19 infection from the novel coronavirus by targeting both the spike protein on SARS-CoV-2, as well as the angiotensin converting enzyme 2 (ACE2) receptor that it binds to on human cells. The study was led by neuroscientists Thomas J. “TJ”

Antibody 105

Antibody Protein Bacteria In-Vitro 105

XTalks

FEBRUARY 19, 2025

It occurs when a genetic error causes the overproduction of a protein called CSF1, which attracts inflammatory cells to the joint, often causing pain, swelling and reduced mobility. In 2024, Deciphera was acquired by ONO Pharmaceutical for $2.4 TGCT is a rare, non-cancerous tumor that develops inside or near joints.

FDA Approval 59

FDA Approval Drugs Trials Clinical Trials 59

pharmaphorum

SEPTEMBER 12, 2022

Everyone’s genetic makeup differs, and each person’s cancer experience is unique to them – how cancer develops, how fast it spreads, which drugs it responds to, and more. Furthermore, each cancer has various gene changes – also referred to as the genetic makeup of cancer. Tailored oncology. About the author.

Genome 105

Genome Genomics Clinical Trials Clinical Trials 105

XTalks

JANUARY 3, 2024

In individuals affected by ATTR, which includes both hereditary and wild-type (non-hereditary) variants, the TTR protein forms fibrils that accumulate in various tissues. These tissues comprise peripheral nerves, the heart, gastrointestinal system, eyes, kidneys, central nervous system, thyroid and bone marrow.

FDA Approval 105

FDA Approval Protein RNA Clinical Trials 105

XTalks

MAY 26, 2023

DEB is a genetic disorder characterized by very fragile skin that rips and blisters easily even from minor friction (like rubbing or scratching) or injury, resulting in open wounds that are prone to skin infections and fibrosis. Vyjuvek is also the first drug approved to treat the disease and is Krystal’s first approved product.

Gene Therapy 97

Gene Therapy Gene FDA Approval Dermatology 97

XTalks

JUNE 16, 2021

The company’s candidate recombinant nanoparticle protein-based COVID-19 vaccine, NVX-CoV2373, is being evaluated in the PREVENT-19 (the PRE-fusion protein subunit Vaccine Efficacy Novavax Trial COVID-19) Phase III trial, which has close to 30,000 participants across 119 states in the US and Mexico.

Vaccination 98

Vaccination Vaccine Protein Trials 98

XTalks

OCTOBER 16, 2024

Hympavzi reduces the activity of TFPI, a naturally occurring anticoagulation protein. This is Pfizer’s second FDA-approved treatment for a rare genetic blood disorder this year. This action increases the amount of thrombin, a critical enzyme in blood clotting, helping to prevent bleeding episodes.

FDA Approval 105

FDA Approval Trials Clinical Trials Clinical Trials 105

XTalks

SEPTEMBER 15, 2020

A vaccine developed by Swedish company Diamyd Medical has demonstrated significant treatment efficacy in a predefined genetic subgroup of individuals with type 1 diabetes in a Phase IIb clinical trial. Specifically, the vaccine contains human recombinant glutamate decarboxylase 65 (GAD65) protein conjugated to aluminum hydroxide (GAD-alum).

Vaccination 103

Vaccination Vaccine Insulin Trials 103

XTalks

MARCH 13, 2024

Related: Transforming Eye Care: Innovating New Glaucoma and Dry Eye Disease Treatments — Featuring Pierre Simon, VP Marketing, Sight Sciences – Xtalks Life Science Podcast Ep. There are also studies examining gene therapy-based techniques to repair or replace genetic defects contributing to this disease.

Gene Therapy 111

Gene Therapy Gene Life Science DNA 111

XTalks

NOVEMBER 6, 2020

The Burnaby, BC-based company developed the oral DNA-based vaccine using its proprietary bacTRL Gene Therapy Platform, which uses genetically modified bifidobacteria as carriers of genetic vaccine elements on a DNA plasmid. Related: Red Meat Allergy Test Gets FDA Clearance. “We

Clinical Trials 75

Clinical Trials Clinical Trials Vaccination Vaccine 75

XTalks

MAY 15, 2023

Fabry disease, also known as Anderson-Fabry disease, is a rare genetic disorder that falls under the category of lysosomal storage diseases. Protalix BioTherapeutics focuses on the production, development and commercialization of recombinant therapeutic proteins.

FDA Approval 98

FDA Approval Gene Genetics Clinical Trials 98

XTalks

AUGUST 17, 2020

As DMD is caused by a lack of functional dystrophin protein, which supports and strengthens muscle fibers, therapies designed to treat this rare genetic disorder have focused on exon skipping to avoid the area of the dystrophin gene that is mutated and produce a nearly full-length dystrophin protein.

Drugs 105

Drugs Clinical Trials Clinical Trials Gene 105

Pharmaceutical Technology

JUNE 21, 2023

Life sciences venture capital firm Flagship Pioneering has unveiled Empress Therapeutics, a small molecule drug development startup. These span multiple structural classes and target several classes of proteins, including cytokines, enzymes, G protein-coupled receptors (GPCRs), and ion channels.

Development 130

Development Drugs Protein Life Science 130

The Pharma Data

SEPTEMBER 15, 2020

The companies will receive priority admission or renewal for one year of lab bench space with access to core facilities at the MBC BioLabs life sciences incubator, including access to Amgen ‘s scientific experts and business leaders to help advance their scientific programs.

Life Science 52

Life Science Protein Antibody Scientist 52

XTalks

MAY 12, 2023

Rett syndrome is a rare genetic disorder that predominantly affects girls and leads to severe physical and cognitive impairments. The MeCP2 protein plays a crucial role in regulating the activity of genes involved in brain development. Dr. Bishop: Rett syndrome is a genetic disorder caused by a mutation in the MECP2 gene.

FDA Approval 97

FDA Approval Genetics Trials Drugs 97

pharmaphorum

MARCH 28, 2022

AION Labs’ third call for applications seeks computational biologists, bioinformatics and cheminformatics scientists, AI researchers, and antibody or protein engineers at academic and industry research labs worldwide to assemble a fully funded start-up company. From there, they evaluate what kind of antibodies are produced.

Pharma Companies 98

Pharma Companies Antibody Protein Development 98

XTalks

FEBRUARY 19, 2024

Moderna’s vaccine not only targets gB but also incorporates a second target, a five-unit protein complex vital for the virus’ ability to infect epithelial cells in the mouth and nose. 1990s: The earliest vaccine development efforts were on live attenuated vaccines and the targeting of specific CMV proteins such as gB.

Vaccination 59

Vaccination Vaccine Trials Clinical Trials 59

XTalks

APRIL 3, 2024

The RBCs in circulation are marked by proteins in the complement system for removal by the spleen and liver. AstraZeneca is also venturing into cell therapy and genetic medicine. The complication occurs in these patients after the use of C5 inhibitors because C5 inhibition enables RBCs to survive and circulate.

FDA Approval 102

FDA Approval Sales Trials Development 102

XTalks

JUNE 15, 2022

The Novavax candidate NVX-CoV2373 is a protein-based vaccine developed using recombinant nanoparticle technology. protein that triggers the immune system to generate antibodies against the virus. If approved, NVX-CoV2373 would become the first available protein-based vaccine against COVID-19 in the US. Clinical Trial Results.

Vaccination 59

Vaccination Vaccine Immune Response Protein 59

XTalks

OCTOBER 20, 2023

Hereditary ATTR (ATTRv) amyloidosis occurs due to mutations in the TTR gene, which causes the liver to produce structurally abnormal transthyretin (TTR) protein with a tendency to misfold. Using CRISPR/Cas9, it knocks out the faulty TTR gene that leads to the production of abnormal TTR protein.

In-Vivo 52

In-Vivo Gene Editing Trials Gene 52

XTalks

NOVEMBER 23, 2020

Developed by researchers at the University of Oxford, the COVID vaccine is an adenovirus vector-based vaccine derived from chimpanzees that contains a genetically engineered virus that causes the common cold in chimpanzees, along with the spike protein of the SARS-CoV-2 coronavirus.

Vaccination 97

Vaccination Vaccine Clinical Trials Clinical Trials 97

XTalks

DECEMBER 12, 2023

Efficacy: By comparing with baseline data, clinicians can discern changes in key imaging biomarkers, from the size of brain structures like grey matter, white matter and CSF, to the size of an infarct or the presence of specific proteins like tau or amyloid.

Trials 111

Trials Clinical Trials Clinical Trials Genetics 111

XTalks

SEPTEMBER 17, 2020

Dietary changes, including restriction of salt and animal protein, are also recommended. Symptoms and Etiology: Characterized by progressive muscle weakness and atrophy, Duchenne muscular dystrophy (DMD) is an X-linked genetic condition that primarily affects males. Lipodystrophy. Prevalence: 1 in 10 million.

Trials 98

Trials Gene Hormones Clinical Trials 98

XTalks

AUGUST 6, 2020

TSC is a rare genetic disease that affects approximately 1 in 6,000 people. The disease is caused by mutations on the TSC1 and TSC2 genes, which produce the proteins hamartin and tuberin, respectively.

FDA Approval 64

FDA Approval Protein Containment Genetic Disease 64

The Pharma Data

OCTOBER 19, 2020

20, 2020 /PRNewswire/ — Caris Life Sciences® , a leading innovator in molecular science focused on fulfilling the promise of precision medicine, announced today that Winship Cancer Institute of Emory University (Winship) has joined Caris’ Precision Oncology Alliance (The Alliance/POA). . SOURCE Caris Life Sciences.

Life Science 52

Life Science Clinical Trials Clinical Trials RNA 52

XTalks

AUGUST 29, 2022

In addition, following different treatment regimens, cancer cells confer genetic mutations that make these cells even more challenging for the body to recognize. Cytokines are signaling proteins produced by immune cells. Cancer cells are notoriously difficult for immune cells to target and remove.

Clinical Trials 95

Clinical Trials Clinical Trials Trials Drugs 95

XTalks

SEPTEMBER 8, 2020

The genetic material contains SARS-CoV-2 spike protein. The vaccine uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus that causes infections in chimpanzees. The Phase 3 trial is being implemented as part of Operation Warp Speed.

Manufacturing 83

Manufacturing Vaccination Vaccine Allergies 83

XTalks

JANUARY 3, 2025

FCS is a rare genetic disorder that prevents the body from properly breaking down triglycerides (a type of fat in the blood), leading to dangerously high levels. This can result in acute pancreatitis (inflammation of the pancreas), a life-threatening condition causing severe abdominal pain and other health complications.

FDA Approval 59

FDA Approval Drugs Clinical Trials Clinical Trials 59

XTalks

FEBRUARY 27, 2023

Alpha-mannosidosis is an extremely rare genetic metabolic disease affecting approximately one in 500,000 people. The lysosomal storage disorder is caused by mutations in the MAN2B1 gene, which codes for lysosomal alpha-mannosidase, an enzyme that degrades glycoproteins (proteins attached to sugar residues).

FDA Approval 52

FDA Approval Life Science Containment Genetics 52

XTalks

JUNE 30, 2023

Hemophilia A is a rare genetic bleeding disorder that is caused by a mutation in the gene that encodes the key blood clotting protein factor VIII (FVIII). Hemophilia A affects approximately one in 10,000 individuals and has a higher incidence than hemophilia B.

Gene Therapy 98

Gene Therapy Gene FDA Approval Antibody 98

XTalks

OCTOBER 4, 2024

Using Drosophila or fruit flies, the researchers discovered that astrocytes release a signaling protein, Fog, which activates the Formin protein pathway, facilitating actin filament movement essential for neural stem cell division and brain repair​. Additionally, 17.7

Genetics 52

Genetics Botox Research Development 52

XTalks

SEPTEMBER 16, 2024

HAE is a rare genetic condition that causes episodes of severe swelling in various parts of the body, including the face, hands, feet and airway. These attacks can be unpredictable, often leading to life-threatening situations when they affect the throat or lungs.

Protein 52

Protein Genetics Trials Allergies 52

The Pharma Data

DECEMBER 8, 2020

December is bringing frost in the North and plenty of cold hard cash for these life sciences companies. . European venture capital firm Forbion rounded up $545 million for its fifth life sciences fund. The rest will be invested in “highly impactful existing companies.”

RNA 52

RNA Antibody Life Science Protein 52

The Pharma Data

JANUARY 20, 2021

Franchi is an experienced board member, finance executive and operational leader with more than three decades of experience in the life sciences industry. Franchi brings to Dynacure’s Board over 30 years of experience in the biotechnology and life sciences industry where she has held senior financial management roles at both U.S.

Life Science 40

Life Science Development Genetics Production 40

XTalks

OCTOBER 8, 2024

SMA is a genetic neuromuscular disease causing progressive muscle weakness and loss of motor function. Apitegromab is a monoclonal antibody that selectively binds to and inhibits myostatin, a protein that limits muscle growth.

Trials 52

Trials Antibody Genetics Medicine 52